Drugs Made In America Acquisition Corp. Units Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition Corp. Units cash flow-to-debt ratio. Drugs Made In America Acquisition Corp. Units (DMAAU) has a Cash Flow-to-Debt Ratio of -0.02x as of March 2026, meaning its operating cash flow of $-125.18K could theoretically repay 0% of its total liabilities ($7.28 Million) in one year. Check how high is Drugs Made In America Acquisition Corp. 's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Drugs Made In America Acquisition Corp. Units (2024–2025)
Cash flow-to-debt ratio of Drugs Made In America Acquisition Corp. Units from 2024 to 2025. Historical debt coverage capacity for Drugs Made In America Acquisition Corp. Units across 2 annual periods. Check DMAAU total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Drugs Made In America Acquisition Corp. Units Cash Flow-to-Debt Ratio by Year (2024–2025)
Drugs Made In America Acquisition Corp. Units cash flow-to-debt ratio by year from 2024 to 2025. Year-by-year debt coverage analysis for Drugs Made In America Acquisition Corp. Units. For the full cash flow conversion analysis, see Drugs Made In America Acquisition Corp. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $795.67 | — |